Vaxart Inc is a biotechnology company focused on developing oral vaccines based on its proprietary platform technology
The company aims to create innovative vaccines that are not only effective but also easy to administer, eliminating the need for needles. Vaxart's research and development primarily targets infectious diseases, with a particular emphasis on creating solutions for viral infections and other public health challenges. Through its unique oral delivery system, Vaxart strives to enhance patient compliance and broaden access to vaccination, ultimately contributing to global health improvement.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc. (NASDAQVXRT) on behalf of long-term stockholders following a class action complaint that was filed against Vaxart on August 24, 2020 with a Class Period from June 25, 2020 to July 25, 2020. Our investigation concerns whether the board of directors of Vaxart have breached their fiduciary duties to the company.
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Velodyne Lidar, Inc. (NASDAQVLDR).
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Vaxart, Inc. (NASDAQVXRT).
New York, NY – August 03, 2021 – New COVID-19 cases continue to surge throughout the United States, causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday, California and New York City announced that they would require all government employees to get the coronavirus vaccine or face weekly COVID-19 testing. The White House also revealed that it would not be lifting international travel restrictions or re-opening US land borders to help combat the rising cases. With no clear end in sight to the ongoing pandemic, companies like Sixth Wave Innovations (CSE:SIXW) (OTCQB:SIXWF), Tonix Pharmaceuticals Holdings (NASDAQTNXP), Vaxart NASDAQ:VXRTNASDAQVXRT)(NASDAQ:COCPNASDAQCOCP and Altimune (NASDAQ:ALTNASDAQ) are developing rapid tests and potential treatments to combat the virus.
Palm Beach, FL – September 23, 2021 – FinancialNewsMedia.com News Commentary – The growth in the COVID-19 vaccine market is projected to continue to surge through 2024. This growth is attributable to drastic surge in coronavirus cases across the world, in consort with combined efforts by regional governments and international organizations to support vaccine development as well as setup more of vaccination facilities. The growing government support for vaccine development and the increasing involvement of global organizations in the development of adequate vaccination facilities in endemic regions is anticipated to positively influence the sales of coronavirus vaccine in the upcoming years. Moreover, the strong demand for coronavirus vaccine, the ongoing initiative initiatives by governments to procure the vaccine and the waves of infection are likely to drive the market growth during the forecast period. According to a report from Market Study Report said that Global Covid-19 vaccine Market will be valued at approximately USD 25 billion in the year 2024, while growing rapidly throughout. The report said: “Under the Patient Type segment, Covid-19 market for senior citizens is anticipated to witness the largest market share owing to the focus of the governments to vaccinate the vulnerable population, manufacturing of vaccines being outsourced and also manufacturers collaborating with hospitals and doctors to better understand their demand and meet their requirements will be pushing growth in the market for Covid-19 vaccine during the coming years. Active biotech companies in the market this week include BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), Dynavax Technologies Corporation (NASDAQDVAX), INOVIO NASDAQ: INONASDAQINO)(NASDAQ: NVAXNASDAQNVAX, Vaxart, Inc. (NASDAQ: VXRTNASDAQ).
